Patents by Inventor Subhash Desai

Subhash Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10912744
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: February 9, 2021
    Assignee: KemPharm, Inc.
    Inventor: Subhash Desai
  • Publication number: 20200054582
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 20, 2020
    Inventor: Subhash Desai
  • Patent number: 10463633
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: November 5, 2019
    Assignee: KemPharm, Inc.
    Inventor: Subhash Desai
  • Publication number: 20170105983
    Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 20, 2017
    Inventor: Subhash Desai
  • Patent number: 9511037
    Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e g, immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: December 6, 2016
    Assignee: GENCO SCIENCES LLC
    Inventor: Subhash Desai
  • Publication number: 20130039960
    Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticulate, non-nanoparticulate, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.
    Type: Application
    Filed: October 19, 2012
    Publication date: February 14, 2013
    Inventor: Subhash Desai
  • Publication number: 20110262496
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Application
    Filed: April 25, 2011
    Publication date: October 27, 2011
    Inventor: Subhash Desai
  • Publication number: 20090149431
    Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 11, 2009
    Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlow V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
  • Publication number: 20070202170
    Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
    Type: Application
    Filed: May 4, 2007
    Publication date: August 30, 2007
    Inventors: Subhash Desai, Sreekant Nadkarni, Randy Wald, Gary DeBrincat
  • Patent number: 7220434
    Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: May 22, 2007
    Assignee: Pharmacia Corporation (of Pfizer, Inc.)
    Inventors: Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat
  • Patent number: 7172769
    Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller than 1 ?m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: February 6, 2007
    Assignee: Pharmacia Corporation
    Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
  • Publication number: 20050267302
    Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
    Type: Application
    Filed: December 4, 2003
    Publication date: December 1, 2005
    Applicant: G.D. Searle & Co.
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
  • Publication number: 20050261261
    Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.
    Type: Application
    Filed: February 7, 2005
    Publication date: November 24, 2005
    Applicant: Pharmacia Corporation
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
  • Publication number: 20050250748
    Abstract: Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.
    Type: Application
    Filed: August 6, 2003
    Publication date: November 10, 2005
    Applicant: G. D. Searle & Co.
    Inventors: John Alexander, Barbara Roniker, Subhash Desai
  • Publication number: 20050159594
    Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
    Type: Application
    Filed: July 16, 2004
    Publication date: July 21, 2005
    Applicant: Pharmacia Corporation
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn L. Stahl, Joseph Wieczorek, Chris Yan
  • Publication number: 20040265382
    Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller tban 1 &mgr;m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.
    Type: Application
    Filed: July 30, 2002
    Publication date: December 30, 2004
    Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
  • Publication number: 20040242640
    Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
    Type: Application
    Filed: February 23, 2004
    Publication date: December 2, 2004
    Inventors: Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat
  • Publication number: 20040077611
    Abstract: Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.
    Type: Application
    Filed: May 19, 2003
    Publication date: April 22, 2004
    Applicant: G.D. Searle & Co.
    Inventors: John C. Alexander, Barbara Roniker, Subhash Desai
  • Publication number: 20030212053
    Abstract: There is provided a pharmaceutical composition comprising eplerenone in solid particulate form, wherein at least 90% of the eplerenone particles are smaller than about 15 &mgr;m, for example about 0.01 &mgr;m to about 1 &mgr;m, in diameter. The composition can be adapted for oral administration, for example as a tablet or capsule comprising eplerenone in a unit dosage amount of about 10 mg to about 1000 mg and one or more excipients.
    Type: Application
    Filed: April 16, 2003
    Publication date: November 13, 2003
    Inventors: Shilpa S. Thosar, Rajeev D. Gokhale, Subhash Desai, Dwain S. Tolbert
  • Publication number: 20030083493
    Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.
    Type: Application
    Filed: July 9, 2002
    Publication date: May 1, 2003
    Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlon V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan